person · Reporting owner
GAROFALO ELIZABETH A.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| Alector, Inc.ALEC · Entity 6051 | Director | June 17, 2026 | June 17, 2026 |
| EXICURE, INC.XCUR · Entity 8068 | Director | June 13, 2022 | June 15, 2022 |
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 01, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,489 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 33,489 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Alector, Inc.
Report date June 17, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,650 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 28,700 · Balance 118,650 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-16 | Direct | 9,450 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 9,450 · Balance 9,450 F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.
EXICURE, INC.
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2032-06-12 | Direct | 50,000 |
Reported balance
After 2022-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date.
Xenon Pharmaceuticals Inc.
Report date June 01, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 2,645 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 2,645 · Balance 2,645 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,593 |
Reported balance
After 2026-06-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-03 · Grant · Acquired 1,593 · Balance 1,593 F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.46 · Expires 2036-06-02 | Direct | 10,507 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 10,507 · Balance 10,507 F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2021 Filed Oct 1, 2021 21:33 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,918 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-058556 · doc4.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 00:00 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 33,235 | $0.00 Strike: $24.26 | $0.00 |
DisclosureSEC source: 0001209191-21-057851 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,235 Underlying: Common Stock · 33,235 shares Expires 2031-09-23 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on September 23, 2022 and 1/48th of the shares vest monthly thereafter. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043039 · doc4.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,391 Underlying: Common Stock · 6,391 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,637 | $0.00 Strike: $24.88 | $0.00 |
DisclosureSEC source: 0001209191-21-043039 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,637 Underlying: Common Stock · 11,637 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 01:00 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001209191-21-038055 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:14 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-21-038319 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 23:57 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-21-018736 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: The shares subject to the option vest in 36 substantially equal monthly installments from the vesting commencement date of March 5, 2021, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:04 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 3,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052665 · doc4.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:04 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 6,865 | $0.00 Strike: $40.41 | $0.00 |
DisclosureSEC source: 0001209191-20-052665 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,865 Underlying: Common Stock · 6,865 shares Expires 2030-09-28 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in two equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.